News & Updates
Filter by Specialty:
Antibiotics identified as culprit for older-onset IBD
Antibiotic use appears to be harmful for older adults, with a recent study showing that regardless of class, the drugs raise the risk of developing inflammatory bowel disease (IBD).
Antibiotics identified as culprit for older-onset IBD
06 Jun 2022Polycythemia ups risk of MACE, VTE in men on testosterone therapy
Men receiving testosterone therapy (TT) who develop polycythemia are at greater risk for major adverse cardiovascular events (MACE) and venous thromboembolism (VTE) in the first year of therapy, according to a recent study.
Polycythemia ups risk of MACE, VTE in men on testosterone therapy
06 Jun 2022Early ivermectin use does not confer benefit for COVID-19
In outpatients with an early diagnosis of COVID-19 at high risk for serious illness, treatment with the antiparasitic ivermectin did not reduce the incidence of hospital admission due to disease progression or of prolonged emergency department observation, findings from the TOGETHER trial suggest.
Early ivermectin use does not confer benefit for COVID-19
06 Jun 2022Iatrogenic tumour seeding not a risk factor for metachronous CRC
In patients with colorectal cancer (CRC), biopsy of nontumour sites after biopsy of the primary cancer is unlikely to cause metachronous cancers, a study reports.
Iatrogenic tumour seeding not a risk factor for metachronous CRC
06 Jun 2022Vision impairment linked to depression, anxiety among kids
Children with vision impairment often experience greater symptoms of depression and anxiety, according to a recent study. Surgical treatment helps improve these mental health symptoms.
Vision impairment linked to depression, anxiety among kids
06 Jun 2022Elacestrant ups PFS vs SoC ET in ER-positive, HER2-negative advanced breast cancer
Elacestrant, a novel oral selective oestrogen receptor (ER) degrader, significantly improves progression-free survival (PFS) vs standard-of-care (SoC) endocrine therapy (ET) in patients with ER-positive, HER2-negative advanced breast cancer whose disease progressed after 1–2 prior lines of ET and a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, results of the phase III EMERALD trial have shown.